OBJECTIVE: To evaluate the intra- and inter-laboratory reproducibility of a new standard for susceptibility testing of fermentative yeasts. This standard is based on the M27-A procedure of the National Committee for Clinical Laboratory Standards (NCCLS), but incorporates several modifications, including spectrophotometric growth-dependent endpoint reading. METHODS: Nine laboratories participated in the study. Common material lots were used to test six Candida species (one each of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and C. lusitaniae), and two quality control strains (C. krusei ATCC6258 and C. parapsilosis ATCC22019). Triplicate testing on three separate days was performed in microtiter format with RPMI-2% glucose, pH 7.0. Flucytosine, fluconazole and itraconazole were tested. In total, 3888 MIC values were included in the analyses. Reproducibility was calculated by means of agreement (percentage of MICs within one two-fold dilution of the mode) and intraclass correlation coefficient (ICC, maximum value of 1). RESULTS: The average intra-laboratory agreements were 99% and 96% after 24 h and 48 h of incubation, respectively, with ICCs of 0.98 and 0.97 (P < 0.05). Two strains exhibiting a trailing effect showed intra-laboratory agreement of 92% and ICCs of < 0.91 at 48 h. The inter-laboratory agreement was 94% and 88% after 24 h and 48 h, respectively, with ICCs of 0.93 and 0.91 (P < 0.05). Lower values of agreement and ICCs were obtained for strains exhibiting trailing after 48 h of incubation. Itraconazole yielded the lowest values of reproducibility. CONCLUSION: The new procedure of EUCAST for antifungal susceptibility testing is a reproducible method within and between laboratories and offers several advantages over the NCCLS approved method.
OBJECTIVE: To evaluate the intra- and inter-laboratory reproducibility of a new standard for susceptibility testing of fermentative yeasts. This standard is based on the M27-A procedure of the National Committee for Clinical Laboratory Standards (NCCLS), but incorporates several modifications, including spectrophotometric growth-dependent endpoint reading. METHODS: Nine laboratories participated in the study. Common material lots were used to test six Candida species (one each of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and C. lusitaniae), and two quality control strains (C. kruseiATCC6258 and C. parapsilosis ATCC22019). Triplicate testing on three separate days was performed in microtiter format with RPMI-2% glucose, pH 7.0. Flucytosine, fluconazole and itraconazole were tested. In total, 3888 MIC values were included in the analyses. Reproducibility was calculated by means of agreement (percentage of MICs within one two-fold dilution of the mode) and intraclass correlation coefficient (ICC, maximum value of 1). RESULTS: The average intra-laboratory agreements were 99% and 96% after 24 h and 48 h of incubation, respectively, with ICCs of 0.98 and 0.97 (P < 0.05). Two strains exhibiting a trailing effect showed intra-laboratory agreement of 92% and ICCs of < 0.91 at 48 h. The inter-laboratory agreement was 94% and 88% after 24 h and 48 h, respectively, with ICCs of 0.93 and 0.91 (P < 0.05). Lower values of agreement and ICCs were obtained for strains exhibiting trailing after 48 h of incubation. Itraconazole yielded the lowest values of reproducibility. CONCLUSION: The new procedure of EUCAST for antifungal susceptibility testing is a reproducible method within and between laboratories and offers several advantages over the NCCLS approved method.
Authors: Frank C Odds; Marie-Elisabeth Bougnoux; Duncan J Shaw; Judith M Bain; Amanda D Davidson; Dorothée Diogo; Mette D Jacobsen; Maud Lecomte; Shu-Ying Li; Arianna Tavanti; Martin C J Maiden; Neil A R Gow; Christophe d'Enfert Journal: Eukaryot Cell Date: 2007-04-06
Authors: Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-10-27 Impact factor: 3.000
Authors: A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij Journal: J Clin Microbiol Date: 2005-08 Impact factor: 5.948
Authors: E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela Journal: Antimicrob Agents Chemother Date: 2007-03-19 Impact factor: 5.191
Authors: Frank C Odds; Mary F Hanson; Amanda D Davidson; Mette D Jacobsen; Pauline Wright; Julie A Whyte; Neil A R Gow; Brian L Jones Journal: J Med Microbiol Date: 2007-08 Impact factor: 2.472